Clinical Trial

Adverse Effects of ATG/ALG Therapy in Aplastic Anemia

Recruiting
View on ClinicalTrials.gov →
Summary
This prospective, single-center, observational cohort study aims to systematically observe and describe the clinical characteristics of adverse reactions in patients with aplastic anemia undergoing ATG (Anti-Thymocyte Globulin) /ALG (Anti-Lymphocyte Globulin) treatment, providing a data foundation for the development of relevant management strategies. This study plans to enroll 200 aplastic anemia patients undergoing ATG/ALG treatment
Trial Details
NCT Number NCT07461116
Lead Sponsor Institute of Hematology & Blood Diseases Hospital, China
Conditions Aplastic Anaemia
Enrollment 200 participants
Start Date 2026-02-23
Primary Completion 2027-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-03-10